166 related articles for article (PubMed ID: 30228940)
1. Duokines: a novel class of dual-acting co-stimulatory molecules acting in cis or trans.
Fellermeier-Kopf S; Gieseke F; Sahin U; Müller D; Pfizenmaier K; Kontermann RE
Oncoimmunology; 2018; 7(9):e1471442. PubMed ID: 30228940
[TBL] [Abstract][Full Text] [Related]
2. Fc-based Duokines: dual-acting costimulatory molecules comprising TNFSF ligands in the single-chain format fused to a heterodimerizing Fc (scDk-Fc).
Aschmoneit N; Kocher K; Siegemund M; Lutz MS; Kühl L; Seifert O; Kontermann RE
Oncoimmunology; 2022; 11(1):2028961. PubMed ID: 35083097
[TBL] [Abstract][Full Text] [Related]
3. Advancing targeted co-stimulation with antibody-fusion proteins by introducing TNF superfamily members in a single-chain format.
Fellermeier S; Beha N; Meyer JE; Ring S; Bader S; Kontermann RE; Müller D
Oncoimmunology; 2016; 5(11):e1238540. PubMed ID: 27999756
[TBL] [Abstract][Full Text] [Related]
4. Expression of tumour necrosis factor (TNF) ligand superfamily co-stimulatory molecules CD30L, CD27L, OX40L, and 4-1BBL in murine hearts with acute myocarditis caused by Coxsackievirus B3.
Seko Y; Takahashi N; Oshima H; Shimozato O; Akiba H; Takeda K; Kobata T; Yagita H; Okumura K; Azuma M; Nagai R
J Pathol; 2001 Dec; 195(5):593-603. PubMed ID: 11745696
[TBL] [Abstract][Full Text] [Related]
5. A Single-Chain-Based Hexavalent CD27 Agonist Enhances T Cell Activation and Induces Anti-Tumor Immunity.
Thiemann M; Richards DM; Heinonen K; Kluge M; Marschall V; Merz C; Redondo Müller M; Schnyder T; Sefrin JP; Sykora J; Fricke H; Gieffers C; Hill O
Front Oncol; 2018; 8():387. PubMed ID: 30298117
[TBL] [Abstract][Full Text] [Related]
6. Expression of tumour necrosis factor (TNF) receptor/ligand superfamily co-stimulatory molecules CD40, CD30L, CD27L, and OX40L in murine hearts with chronic ongoing myocarditis caused by coxsackie virus B3.
Seko Y; Takahashi N; Oshima H; Shimozato O; Akiba H; Kobata T; Yagita H; Okumura K; Azuma M; Yazaki Y
J Pathol; 1999 Aug; 188(4):423-30. PubMed ID: 10440754
[TBL] [Abstract][Full Text] [Related]
7. IL15-Based Trifunctional Antibody-Fusion Proteins with Costimulatory TNF-Superfamily Ligands in the Single-Chain Format for Cancer Immunotherapy.
Beha N; Harder M; Ring S; Kontermann RE; Müller D
Mol Cancer Ther; 2019 Jul; 18(7):1278-1288. PubMed ID: 31040163
[TBL] [Abstract][Full Text] [Related]
8. Tumor-targeted costimulation with antibody-fusion proteins improves bispecific antibody-mediated immune response in presence of immunosuppressive factors.
Sapski S; Beha N; Kontermann R; Müller D
Oncoimmunology; 2017; 6(12):e1361594. PubMed ID: 29209565
[TBL] [Abstract][Full Text] [Related]
9. Regulation of CD40 ligand expression on naive CD4 T cells: a role for TCR but not co-stimulatory signals.
Jaiswal AI; Dubey C; Swain SL; Croft M
Int Immunol; 1996 Feb; 8(2):275-85. PubMed ID: 8671613
[TBL] [Abstract][Full Text] [Related]
10. A novel antibody-4-1BBL fusion protein for targeted costimulation in cancer immunotherapy.
Müller D; Frey K; Kontermann RE
J Immunother; 2008 Oct; 31(8):714-22. PubMed ID: 18779748
[TBL] [Abstract][Full Text] [Related]
11. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
Khawli LA; Hu P; Epstein AL
Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
[TBL] [Abstract][Full Text] [Related]
12. Structural and biological features of the TNF receptor and TNF ligand superfamilies: interactive signals in the pathobiology of Hodgkin's disease.
Gruss HJ; Duyster J; Herrmann F
Ann Oncol; 1996; 7 Suppl 4():19-26. PubMed ID: 8836404
[TBL] [Abstract][Full Text] [Related]
13. Influence of antigen density and immunosuppressive factors on tumor-targeted costimulation with antibody-fusion proteins and bispecific antibody-mediated T cell response.
Sapski S; Beha N; Kontermann RE; Müller D
Cancer Immunol Immunother; 2020 Nov; 69(11):2291-2303. PubMed ID: 32504247
[TBL] [Abstract][Full Text] [Related]
14. Human sunlight-induced basal-cell-carcinoma-associated dendritic cells are deficient in T cell co-stimulatory molecules and are impaired as antigen-presenting cells.
Nestle FO; Burg G; Fäh J; Wrone-Smith T; Nickoloff BJ
Am J Pathol; 1997 Feb; 150(2):641-51. PubMed ID: 9033277
[TBL] [Abstract][Full Text] [Related]
15. Co-expression of CD40L with CD70 or OX40L increases B-cell viability and antitumor efficacy.
Shin CA; Cho HW; Shin AR; Sohn HJ; Cho HI; Kim TG
Oncotarget; 2016 Jul; 7(29):46173-46186. PubMed ID: 27323820
[TBL] [Abstract][Full Text] [Related]
16. Artificial antigen-presenting cells expressing CD80, CD70, and 4-1BB ligand efficiently expand functional T cells specific to tumor-associated antigens.
Zeng W; Su M; Anderson KS; Sasada T
Immunobiology; 2014 Aug; 219(8):583-92. PubMed ID: 24713579
[TBL] [Abstract][Full Text] [Related]
17. A T cell lymphoma can provide potent co-stimulatory effects to T cells that are not mediated by B7-1, B7-2, CD40, HSA or CD70.
Nieland JD; Kruisbeek AM
Int Immunol; 1995 Nov; 7(11):1827-38. PubMed ID: 8580081
[TBL] [Abstract][Full Text] [Related]
18. Combining antibody-directed presentation of IL-15 and 4-1BBL in a trifunctional fusion protein for cancer immunotherapy.
Kermer V; Hornig N; Harder M; Bondarieva A; Kontermann RE; Müller D
Mol Cancer Ther; 2014 Jan; 13(1):112-21. PubMed ID: 24198185
[TBL] [Abstract][Full Text] [Related]
19. Combination of a bispecific antibody and costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy.
Hornig N; Kermer V; Frey K; Diebolder P; Kontermann RE; Müller D
J Immunother; 2012 Jun; 35(5):418-29. PubMed ID: 22576347
[TBL] [Abstract][Full Text] [Related]
20. An expanding role for CD40L and other tumor necrosis factor superfamily ligands in HIV infection.
Kornbluth RS
J Hematother Stem Cell Res; 2002 Oct; 11(5):787-801. PubMed ID: 12427285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
